Skip to main content
≥99.0% HPLC Verified • SEPA Bank & Crypto • Min. Order €220
Metabolic Research 3 min read

Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry

Compiled & reviewed by SwissLab Peptide Biochemistry Editorial Desk — Preclinical Literature & Receptor Mechanism Review Desk
Editorial Standards
Analytical Summary

Survodutide (BI 456906) and Mazdutide (IBI362) are acylated dual GLP-1R/GCGR agonists that pair satiety signaling with hepatic glucagon-driven lipid oxidation, whereas Retatrutide (LY3437943) adds potent GIPR agonism as a 39-residue triple receptor agonist.

Key Research Takeaways
  • Survodutide (BI 456906) is an oxyntomodulin-derived dual GLP-1R/GCGR agonist incorporating a C18 fatty diacid for albumin binding.
  • Mazdutide (IBI362 / LY3305677) is a mammalian oxyntomodulin analogue engineered for balanced dual GLP-1R and GCGR signaling.
  • Retatrutide (LY3437943) expands the scaffold to triple GLP-1R, GIPR, and GCGR agonism with picomolar GIPR dominance.
  • Comparing Survodutide vs Tirzepatide isolates GCGR-driven hepatic steatosis clearance versus GIPR-mediated insulinotropic pathways.
Analytical & Handling Reference Matrix
Survodutide (CAS / MW) 2805997-46-8 | 4231.65 g/mol | Dual GLP-1R / GCGR
Mazdutide (CAS / MW) 2259884-03-0 | 4563.06 g/mol | Dual GLP-1R / GCGR
Retatrutide (CAS / MW) 2381089-83-2 | 4731.33 g/mol | Triple GLP-1R / GIPR / GCGR
Lipidation Strategy C18/C20 fatty-diacid side chains for reversible serum albumin binding
Analytical Verification ≥99.0% RP-HPLC (C18) + High-Resolution ESI-MS (±0.1 Da)
Recommended Storage Lyophilized -20°C desiccated; reconstituted 2°C–8°C

1. Survodutide Mechanism of Action: Dual GLP-1R / GCGR Co-Agonism

Survodutide (BI 456906, CAS 2805997-46-8, MW 4231.65 g/mol) is a 29-amino acid acylated peptide engineered from the endogenous gut hormone glucagon/oxyntomodulin template. By combining GLP-1 receptor activation with calibrated glucagon receptor (GCGR) agonism, Survodutide stimulates hepatic β-oxidation, lipolysis, and energy expenditure in preclinical hepatocyte and metabolic models while GLP-1R co-signaling buffers glucagon-induced hyperglycemia. Its C18 fatty-diacid acylation enables reversible albumin binding and enzymatic protection against DPP-4 cleavage.

2. Survodutide vs Mazdutide: Comparing Oxyntomodulin Scaffolds

Both Survodutide and Mazdutide (IBI362 / LY3305677, CAS 2259884-03-0, MW 4563.06 g/mol) are dual GLP-1R/GCGR agonists derived from oxyntomodulin, yet they differ in linker architecture, fatty-diacid chain length (C20 diacid on Mazdutide), and relative GLP-1R:GCGR potency ratios in cAMP accumulation assays. Researchers comparing Survodutide vs Mazdutide evaluate downstream hepatic fat mobilization, amino acid catabolism markers, and receptor internalization kinetics across primary hepatocyte and pancreatic β-cell cultures.

3. Dual GCGR Agonists vs Retatrutide & Tirzepatide

When contrasting Survodutide vs Tirzepatide or Mazdutide vs Tirzepatide, the key experimental axis is GCGR versus GIPR co-activation: Tirzepatide activates GLP-1R and GIPR without meaningful GCGR affinity, whereas Survodutide and Mazdutide engage GLP-1R and GCGR without GIPR signaling. Retatrutide (LY3437943, CAS 2381089-83-2, MW 4731.33 g/mol) unifies all three Class B GPCRs in a single 39-residue backbone, making side-by-side in-vitro assays across Semaglutide, Tirzepatide, Survodutide, Mazdutide, and Retatrutide ideal for dissecting individual receptor contributions to cAMP signaling and mitochondrial thermogenesis.

4. Handling Acylated Incretin Peptides in In-Vitro Assays

Because fatty-diacid acylated peptides are amphiphilic and bind strongly to serum albumin, apparent EC50 values shift markedly depending on BSA/HSA concentration in the assay buffer. Always match albumin concentration (typically 0.1% casein or standardized 1% BSA) across comparative plates, reconstitute lyophilized vials gently in sterile neutral buffer or bacteriostatic water without foaming, and normalize dosing by exact nanomolar concentration using the SwissLab Molarity Calculator.

Peer-Reviewed References & Analytical Standards

  1. Zimmermann T. et al. (2022). BI 456906 (Survodutide): Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism, 66, 101633. [PMID: 36356832 ↗]
  2. Ji L. et al. (2021). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults. EClinicalMedicine / Nature Communications pharmacology studies. [PMID: 34950864 ↗]
  3. Coskun T. et al. (2022). LY3437943 (Retatrutide), a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 34(9), 1234–1247. [PMID: 35985340 ↗]

Referenced Laboratory Research Reagents

Batch-verified SwissLab catalog entries cited in this monograph

All 66 Compounds →
Laboratory Compliance & Handling Protocol

All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.

Related Research Monographs

All monographs (44)

Your Research Cart

0 items selected • Min. order €220

SEPA Bank Transfer & Crypto (BTC, ETH, USDT, USDC, SOL, XMR)
Min €220

Your cart is empty

Browse our catalog of research peptides and reagents (minimum order €220).

Browse Catalog